Herriot Tabuteau, Axsome CEO (Photo by Owen Hoffmann/Patrick McMullan via Getty Images)
Axsome's migraine drug issued CRL a week after the biotech outlined CMC concerns
A week after New York-based Axsome Therapeutics said it expected a CRL for its migraine drug, the biotech reported Monday that the FDA has followed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
